版本:
中国

BRIEF-Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018

May 25 Anika Therapeutics Inc:

* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis

* Anika expects to complete supplemental phase III trial in 2018 and anticipates FDA approval in following year Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐